Evidence map›Paper›PMID 37953758›Full record

ReviewMaterials today. Bio2023

Current advances in niosomes applications for drug delivery and cancer treatment.

Ali Moammeri, Masoumeh Mirzaei Chegeni, Hamidreza Sahrayi, Robabehbeygom Ghafelehbashi, Farkhondeh Memarzadeh, Afsoun Mansouri, Iman Akbarzadeh, Maryam Sadat Abtahi, Faranak Hejabi, Qun Ren

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Niosomal Encapsulation ofPharmaceutics · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Ali MoammeriSchool of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Masoumeh Mirzaei ChegeniDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Hamidreza SahrayiDepartment of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran, Iran.
Robabehbeygom GhafelehbashiDepartment of Materials and Textile Engineering, College of Engineering, Razi University, Kermanshah, Iran.
Farkhondeh MemarzadehDepartment of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran, Iran.
Afsoun MansouriSchool of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Iman AkbarzadehDepartment of Chemical and Petrochemical Engineering, Sharif University of Technology, Tehran, Iran.
Maryam Sadat AbtahiSchool of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Faranak HejabiDepartment of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
Qun RenLaboratory for Biointerfaces, Empa, Swiss Federal Laboratories for Materials Science and Technology, 9014, St. Gallen, Switzerland.
Sharif University of Technology · IRUniversity of Tehran · IRIslamic Azad University Pharmaceutical Sciences Branch · IRIslamic Azad University, Science and Research Branch · IRKharazmi University · IRRazi University · IRSwiss Federal Laboratories for Materials Science and Technology · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of nanotechnology has led to an increased interest in nanocarriers as a drug delivery system that is efficient and safe. There have been many studies addressing nano-scale vesicular systems such as liposomes and niosome is a newer generation of vesicular nanocarriers. The niosomes provide a multilamellar carrier for lipophilic and hydrophilic bioactive substances in the self-assembled vesicle, which are composed of non-ionic surfactants in conjunction with cholesterol or other amphiphilic molecules. These non-ionic surfactant vesicles, simply known as niosomes, can be utilized in a wide variety of technological applications. As an alternative to liposomes, niosomes are considered more chemically and physically stable. The methods for preparing niosomes are more economic. Many reports have discussed niosomes in terms of their physicochemical properties and applications as drug delivery systems. As drug carriers, nano-sized niosomes expand the horizons of pharmacokinetics, decreasing toxicity, enhancing drug solvability and bioavailability. In this review, we review the components and fabrication methods of niosomes, as well as their functionalization, characterization, administration routes, and applications in cancer gene delivery, and natural product delivery. We also discuss the limitations and challenges in the development of niosomes, and provide the future perspective of niosomes.

Indexed as

Niosome functionalizationNiosomes characterizationNiosomes in cancer treatmentNiosomes in gene delivery

Identifiers

PMID37953758
PMCPMC10632535
OpenAlexW4387849811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.